Endocrine Abstracts

Introduction: Excess GH in acromegaly has lipolytic action and detrimental effect on glucose metabolism and insulin signaling. Recent studies have suggested a specific lipodystrophy in patients with acromegaly. Paradoxically, although the visceral adipose tissue (VAT) and intrahepatic lipid were reduced in active acromegaly compared to controls, insulin resistance was increased. Fat was redistributed from subcutaneous and visceral depots to muscle; weight and VAT depots rose w...

Introduction: Pegvisomant (PEG) is an efficient treatment for acromegaly but the recommendation for this treatment is less active due to its high cost. In Romania it is reimbursed in doses up to 30 mg s.c/day or as 40 or 80 mg/week in combination with a somatostatin analog (SSA).Design: Retrospective analysis of 18 consecutive patients treated with PEG for acromegaly (either as monotherapy, or in combination with SSA and/or cabergoline (CAB...

Introduction: Pheochromocytoma (PCC) has a wide spectrum of clinical manifestations, from insidious disease to extreme symptoms. Various mechanisms of catecholamine and other mediators actions were related to the diversity of PCC presentation.Aim: We describe a retrospective study, of patients with PCC from a tertiary hospital, focusing on clinical and biochemical characteristics of PCC depending on means of discovery.Material and ...